Phase 1b/2a, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus

 The main purpose of this study is to explore the safety and tolerability of an investigational (not approved by the United States Food and Drug Administration [FDA]) bacteriophage (a virus that infects and makes copies of itself within bacteria) product, called AP-SA02, given to people who agree to take part in this study (study subjects) and have Staphylococcus aureus Bacteremia (SAB) a type of infection of the blood. For the rest of this document the investigational bacteriophage product will be referred to as "study drug".